All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering Committee About Us Newsletter Contact

Visit:

You're logged in! Click here any time to manage your account or log out.

You're logged in! Click here any time to manage your account or log out.

Steering Committee About Us Newsletter Contact

Types Therapeutics Congresses Trials Expert Opinions DRUG UPDATES

AML Types

2021-11-04T17:27:17.000Z

How would you treat newly diagnosed induction-eligible patients with acute myeloid leukemia?

By Mark Maitland

Featured

Amir Fathi

Nov 4, 2021

Share:

Bookmark this article

How would you treat newly diagnosed induction-eligible patients with acute myeloid leukemia?

Venetoclax + Azacitidine

28%

ARA-C + Ida/daunorubicin

71%

L-PAM, pred + bortezomib

0%

7 votes

The AML Hub was pleased to speak with Amir Fathi, Massachusetts General Hospital, Boston, US. We asked, How would you treat newly diagnosed induction-eligible patients with acute myeloid leukemia?

How would you treat newly diagnosed induction-eligible patients with acute myeloid leukemia?

Fathi highlights that to determine eligibility for intensive cytotoxic chemotherapy, patient's fitness, comorbidities, and functional status are considered. He outlines induction chemotherapy regimens and highlights the two step approach to newly diagnosed AML; intensive chemotherapy, followed by consolidation. Finally, Fathi explains that for less robust patients a gentler regimen including hypomethylating agents or BCL2 inhibitors can be used as an alternative.

More about...

BCL-2 inhibitors Chemotherapy Disease Hypomethylating agents LLMC 2021 Newly diagnosed Venetoclax

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?

1 vote - 3 days left ...

Related articles

Add bookmark

Outcomes with venetoclax in treating AML in real-world settings

The findings demonstrated that the venetoclax-based combination approach was associated with encouraging response rates in first-line settings. Response rates were also found to be...

Mar 24, 2022

Add bookmark

Outcomes with venetoclax in treating AML in real-world settings

The findings demonstrated that the venetoclax-based combination approach was associated with encouraging response rates in first-line...

Mar 24, 2022

Add bookmark

Is venetoclax combined with low-dose chemo and HMA safe and efficacious in older patients with AML?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Tapan Kadia, MD Anderson Cancer Center,...

Dec 21, 2020

Add bookmark

Is venetoclax combined with low-dose chemo and HMA safe and efficacious in older patients with AML?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub...

Dec 21, 2020

Newsletter

Subscribe to get the best content related to AML delivered to your inbox